Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer
1996

Comparing 5 Years of Tamoxifen Treatment for Breast Cancer

Sample size: 342 publication Evidence: low

Author Information

Author(s): HJ Stewart, AP Forrest, D Everington, CC McDonald, JA Dewar, RA Hawkins, RJ Prescott, WD George

Primary Institution: Scottish Cancer Trials Office, The Medical School, University of Edinburgh

Hypothesis

Is continuing tamoxifen treatment beyond 5 years beneficial for women with operable breast cancer?

Conclusion

Continuing tamoxifen treatment beyond 5 years does not significantly improve disease control and may increase the risk of endometrial carcinoma.

Supporting Evidence

  • Patients who continued tamoxifen had a higher number of confirmed relapses, but the difference was not statistically significant.
  • Endometrial carcinomas were only diagnosed in patients who continued tamoxifen beyond 5 years.
  • The study suggests that the benefits of tamoxifen after 5 years are modest compared to the first 5 years of treatment.

Takeaway

This study looked at whether women should keep taking a medicine called tamoxifen for breast cancer after 5 years. It found that taking it longer might not help much and could even cause other problems.

Methodology

Women who were disease-free after 5 years of tamoxifen were randomly assigned to either stop or continue treatment.

Limitations

The sample size was limited, which may not adequately detect small differences between treatment groups.

Participant Demographics

Women with operable breast cancer who were disease-free after 5 years of tamoxifen therapy.

Statistical Information

P-Value

0.064

Confidence Interval

95% CI=0.87-1.85

Statistical Significance

p=0.064

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication